阿帕替尼治疗晚期非小细胞肺癌的近期疗效及不良反应

摘要

Objective:To observe the efficiency and toxicities of Apatinib in the treatment of patients with ad-vanced non-small cell lung cancer(NSCLC).Methods:32 patients with advanced NSCLC in our hospital from Janu-ary 2016 to October 2016 were randomly divided into experimental group and control group.The experimental group was treated by Apatinib and the control group was treated by best support treatment.Observe the short-term effect and adverse reactions after treatment.Results:The objective response rate(ORR)and the disease control rate(DCR) of the experimental group respectively was 11.8% and 52.9%,there was significant difference in DCR between the two groups.The median PFS of the experimental group was 3.1 months and the control group was 1.8 months,showing significant difference.The major toxicity and side effects were high blood pressure,proteinuria and hand-foot syn-drome,the incidence rate was 58.8%(10/17),52.9%(9/17)and 29.4%(5/17)respectively.Conclusion:Apa-tinib is effective for the advanced NSCLC and the toxicity and side effects are tolerable.%目的:观察阿帕替尼治疗晚期非小细胞肺癌的近期疗效及不良反应.方法:选择我院2016年1月至2016年10月收治的晚期非小细胞肺癌患者32例,随机分为阿帕替尼治疗组(实验组)和最佳支持治疗组(对照组),观察治疗后的疗效及不良反应.结果:阿帕替尼组治疗客观缓解率(ORR)为11.8%、疾病控制率(DCR)为52.9%,与最佳支持治疗组比较疾病控制率差异有统计学意义;两组间中位无进展生存期(PFS)分别为3.1个月、1.8个月,差异有统计学意义.患者不良反应较轻,主要为高血压、蛋白尿及手足综合症,发生率分别为58.8%(10/17)、52.9%(9/17)、29.4%(5/17),经治疗后可缓解.结论:阿帕替尼是晚期非小细胞肺癌有效的治疗方法,不良反应小,患者易于耐受.